“…Nevertheless, it has been demonstrated that 5-phosphatases, such as Src homology 2-containing inositol 5-phosphatase (SHIP) in hematopoietic cells [8], Phosphatidylinositol 4,5-Bisphosphate 5-Phosphatase (PIB5PA) in neuritis and melanoma cells [9,10], and Src homology 2-containing inositol 5-phosphatase 2 (SHIP2) in glioblastoma and GC cells, inhibit Akt activation [11,12]. SHIP2, encoded by inositol polyphosphate phosphatase-like 1 (INPPL1), belongs to the phosphoinositide 5-phosphatase family, which has been implicated in some human diseases such as type 2 diabetes, Alzheimer's disease and Opsismodysplasia [13][14][15]. However, the role of SHIP2 in tumorigenesis and tumor progression remains paradoxical: high SHIP2 expression has been found in breast cancer, hepatocellular cancer, non-small cell lung cancer, and colorectal cancer, which correlates with poor survival of patients and contributes to the malignant potential of these tumors [16][17][18][19], whereas reduced expression of SHIP2 in GC promotes tumorigenesis and proliferation of GC via activation of the PI3K/Akt signaling [12], and, in squamous cell carcinoma and glioblastoma cells, SHIP2 inhibits Akt activation and leads to apoptosis and cell cycle arrest [11,20].…”